Alchemab Therapeutics
Business Services · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
East Side Office 1.02, London, Greater L...Website
www.alchemab.comRevenue
$13.3 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
2
1
1
About Alchemab Therapeutics
Alchemab studies the natural antibody responses of individuals who are highly resilient to disease and identifies antibodies uniquely shared in the resilient groups and not seen in disease progressors. The targets to these antibodies are then identified and the antibodies developed into therapies for hard-to-treat diseases which do not have disease modifying approaches. Alchemab's platform integrates data mining and machine learning models of patient-derived immune responses with in vitro and in vivo drug discovery approaches to understand what keeps people well. The goal is to unlock nature's immunological response to disease and harness the company's highly evolved human immune system to find breakthrough drugs. Alchemab was founded in 2019 and is headquartered in London, UK with labs in Cambridge, UK.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alchemab Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Alchemab Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Alchemab Therapeutics has new funding data
Product Launch: Get notified when Alchemab Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Alchemab Therapeutics recently announced quarterly report
Alchemab Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Alchemab Therapeutics
Check if Alchemab Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Alchemab Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Alchemab Therapeutics
Find 3 more new buyers
Compare Similar Companies to Alchemab Therapeutics
Compare insights from companies similar to Alchemab Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Alchemab Therapeutics
$13.3M
51-200
Private
$114M
2019
N/A
Company Profile Activity
Activity Insights
Alchemab Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Alchemab Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Alchemab Therapeutics.
Alchemab Therapeutics financials insights
Gather financial insights about Alchemab Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$82M
2025
Series A
$32M
Alchemab Therapeutics Tech Stack
A closer look at the technologies used by Alchemab Therapeutics
See more technologies
Most Recent Scoops
Open Position
Left Company
Executive Move
Executive Moves, Left Company
Funding
Funding
Open Position
Left Company
Executive Move
Executive Moves, Left Company, Board of Directors
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Alchemab Therapeutics
Sign Up For FreeTo access detailed company insights
Alchemab studies the natural antibody responses of individuals who are highly resilient to disease and identifies antibodies uniquely shared in the resilient groups and not seen in disease progressors. The targets to these antibodies are then identified and the antibodies developed into therapies for hard-to-treat diseases which do not have disease... Read More
